Active Biotech and OXiGENE enter into research collaboration within the field of inflammatory diseases


As a first step, the aim of the collaboration is to evaluate the potential of the benzamide technology for the treatment of inflammatory diseases, such as rheumatoid arthritis and, as a second step, to develop this potential further. The research will be carried out at Active Biotech Research in Lund, Sweden, and will be led by Tomas Leanderson, newly appointed Head of Pre-clinical Research at Active Biotech.

If the first step, which is scheduled to be completed one year from now, is successful it is the intention of the parties to jointly develop the identified drug candidates further.

In my previous position, as Professor of Immunology at Lund University, I have together with Professor Ronald Pero, OXiGENE's Chief Scientific Officer, studied the anti-inflammatory properties of the benzamides and nicotinamides for some years. It gives me great satisfaction to be able to continue this research within Active Biotech, says Tomas Leanderson.

We are very pleased to be entering into research collaboration with OXiGENE in order to evaluate the potential of these new substances within one of our fields of competence, namely inflammatory diseases, comments Sven Andréasson, President and CEO of Active Biotech.

Active Biotech AB (publ)

Sven Andréasson
President and CEO